Quellen

1) Vinson B. Development of Iberogast: clinical evidence for multicomponent herbal mixtures. In: Cooper R, Kronenberg F., editors. Botanical medicine: from bench to bedside. New Rochelle: Mary Ann Liebert 2009; S. 167-189.

2) Ottillinger B, et al. STW 5 (Iberogast®) – a safe and effective standard in the treatment of functional gastrointestinal disorders. Wien Med. Wochenschr. 2013; 163: 65-72.

3) http://www.inspirato.de/pharma-marketing-2015-award.html

4) Layer P, Andresen V, Pehl C, Allescher H. et al. S3-Leitlinie Reizdarmsyndrom: Definition, Pathophysiologie, Diagnostik und Therapie. Gemeinsame Leitlinie der Deutschen Gesellschaft für Verdauungs- und Stoffwechselkrankheiten (DGVS) und der Deutschen Gesellschaft für Neurogastroenterologie und Motilität (DGNM). AWMF-Registriernummer: 021 /016.

5) Heinle H, Hagelauer D, Pascht U, Kelber O, Weiser D. Intestinal spasmolytic effects of STW 5 (Iberogast®) and its components. Phytomedicine 2006; 13: SV 75-79.

6) Hohenester B, Rühl A, Kelber O, Schemann M. the herbal preparation STW-5 (lberogast) has potent and region-specific effects on gastric motility. Neurogastroenterol. Motil. 2004; 16: 765-773.

7) Kroll U, Cordes C, Pharmaceutical prerequisites for a multi-target therapy. Phytomedicine 2006; 13: SV 12-19.

8) Madisch A, Holtmann G, Plein K, et al. Treatment of irritable bowel syndrome with herbal preparations. Aliment Pharmacol. Ther. 2004; 19: 271-279.

9) Melzer J, Rösch W, Reichling J, et al. Metaanalysis: phytotherapy of functional dyspepsia with the herbal drug preparation STW 5 (Iberogast). Aliment Pharmacol. Ther. 2004; 20: 1279-1287.

10) Schemann M, Michel K, Hohenester B, Ruhl A. Region-specific effects of STW 5 and its components in gastric fundus, corpus and antrum. Phytomedicine 2006; 13: SV 90-99.

11) Wegener T, Wagner H. The active components and the pharmacological multi-target principle of STW 5 (Iberogasts). Phytomedicine 2006; 13: SV 20-35.

12) Nieber K, Michael S, Grotzinger K, Rauwald JW, Kelber O. Anti-inflammatory effect of STW 5, STW 6 and isolated extracts on the rat small intestine. Z. Phytotherapie 2008; 29.

13) Wagner H. Multitarget therapy - The future of treatment for more than just function dyspepsia. Phytomedicine 2006; 13: SV 122-129.

14) Vinson BR, Holtmann G. Onset of action and efficiency of STW 5 in the clinical setting in patients with Functional Dyspepsia and Irritable Bowel Syndrome. Gastroenterology 2013; 144: S682 (Mo1881).